MARKET

ENSC

ENSC

Ensysce Biosciences Inc
NASDAQ
0.4011
-0.0112
-2.72%
After Hours: 0.4077 +0.0066 +1.65% 19:28 09/28 EDT
OPEN
0.4110
PREV CLOSE
0.4123
HIGH
0.4225
LOW
0.3990
VOLUME
212.86K
TURNOVER
--
52 WEEK HIGH
2.750
52 WEEK LOW
0.2300
MARKET CAP
7.80M
P/E (TTM)
-0.1457
1D
5D
1M
3M
1Y
5Y
1D
Ensysce Biosciences submits Phase 2 protocol for CY200 to UK MHRA
TipRanks · 4d ago
Weekly Report: what happened at ENSC last week (0914-0918)?
Weekly Report · 09/21 10:25
Ensysce Biosciences advances CRPS program at Painweek 2026
TipRanks · 09/15 13:25
Ensysce Biosciences Advances CRPS Program at Painweek 2026, Contributes to FDA Hearing on Psychedelic Drug Regulation
Barchart · 09/15 08:15
Ensysce professor to speak at FDA public hearing on psychedelic drugs
TipRanks · 09/14 12:20
Weekly Report: what happened at ENSC last week (0907-0911)?
Weekly Report · 09/14 10:31
Ensysce Biosciences' Professor Richard Langford Selected to Speak at FDA Public Hearing on the Potential Future Therapeutic Use of Psychedelic Drugs
Barchart · 09/14 07:00
Weekly Report: what happened at ENSC last week (0831-0904)?
Weekly Report · 09/07 10:24
More
About ENSC
Ensysce Biosciences, Inc. is a clinical-stage pharmaceutical company. It develops solutions for severe pain relief while reducing the potential for opioid misuse, abuse, and overdose. Its pipeline includes an abuse-resistant opioid prodrug technology, the Trypsin Activated Abuse Protection (TAAP) platform, and an over-dose protection opioid prodrug technology, the Multi-Pill Abuse Resistant (MPAR) platform. Its lead product, PF614, is a TAAP extended-release oxycodone and a potential analgesic to treat severe pain. Its second product, PF614-MPAR, is to treat severe pain with the added benefit of oral overdose protection, is a combination product of the TAAP prodrug PF614 with a trypsin inhibitor. Additionally, nafamostat, which is an ingredient in its overdose protection combination products, is also being developed for the intended purpose of treating infection and pulmonary lung diseases. It is also developing novel neuroplastogenic therapies for complex regional pain syndrome.

Webull offers Ensysce Biosciences Inc stock information, including NASDAQ: ENSC real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ENSC stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ENSC stock methods without spending real money on the virtual paper trading platform.